Company news

EMvision Medical Devices Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Stage 3 Recuitment Achieved & FDA Engagement Underway

July 7, 2024

Pilot Production Line Established & $1.25m Grant Received

June 23, 2024

Trial data confirms early ischaemia detection capabilities

May 26, 2024

Stage 2 Insights Confirm Diagnostic & Clinical Viability

March 26, 2024

ASA Milestone Achieved for $0.6m Grant Payment

March 12, 2024

Strategic A$15.28M Investment from Keysight Technologies

February 28, 2024

EMVision Receives $2.58m R&D Rebate & ASA Milestone Achieved

December 17, 2023

Stage 2 Trial Recruitment Tartget Reached & EMU Unveiled

November 26, 2023

AGM CEO Presentation including Latest Imaging Case Studies

November 14, 2023

AGM Chairman's Address

November 14, 2023

Gen 2 Advanced Prototype Assembled

October 23, 2023

Encouraging Interim Clinical Trial Results

October 9, 2023

Appendix 4E & Annual Report to 30 June 2023

August 29, 2023

Latest Imaging and Clinical Trial Insights

August 21, 2023

Clinical Trial Progress & ASA Milestone Achieved

July 26, 2023

Recruitment at Royal Melbourne Hospital Commences

June 28, 2023

$1.75M Manufacturing Grant Payment Received

June 12, 2023

Leadership Transition

May 30, 2023

Stage 2 of Clinical Trial Activated

May 28, 2023

Product Development Milestones & Grant Funding Achieved

April 16, 2023

CEO Half-Year Update

February 27, 2023

Clinical Trial Stage 1 Enrolment Completed

February 20, 2023

Trial Progressing on Target and ASA Milestone Achieved

January 24, 2023

$8.8m In Non-Dilutive Funding To Be Received This Quarter

November 30, 2022

EMVision Commences Clinical Trial

November 29, 2022

AGM Chairman Address and Presentation

November 15, 2022

Portable Brain Scanner Delivered to First Clinical Site

November 13, 2022

EMVision Backed By NSW Medical Devices Fund With $2.5m Grant

November 10, 2022

$5m Modern Manufacturing Initiative Funding Agreement Signed

October 24, 2022

Ethics Approval Received For Multi-Centre Clinical Trial

October 3, 2022

Employee Incentive Plan Issue

September 16, 2022

Appendix 4E & Annual Report to 30 June 2022

August 29, 2022

$5m Modern Manufacturing Initiative Grant Proceeding

August 28, 2022

Centres of Excellence Confirmed as First Two Clinical Sites

July 11, 2022

EMVision Achieves First Responder Milestone

June 26, 2022

EMVision Awarded $5m Non-Dilutive Funding via MMI Grant

May 17, 2022

Pause in Trading

May 16, 2022

EMVision Secures Strategic Agreement With Keysight

May 4, 2022

New Appointments to Clinical Advisory Board

March 8, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

Application for quotation of securities - EMV

December 22, 2021

EMV Technology to be Presented at Prestigious Conference

December 8, 2021

EMVision Receives $3.4m Non-Dilutive Funding this Quarter

December 7, 2021

Notification regarding unquoted securities - EMV

December 1, 2021

Clinical Trial Data Drives Confidence for Expanded Studies

November 29, 2021

AGM Chairmans Address & Presentation

November 25, 2021

AGM Chairman's Address & Presentation

November 24, 2021

FDA Breakthrough Device Application Update

October 5, 2021

ASA & EMVision Sign $8m Project Agreement

September 15, 2021

Appendix 4E & Annual Report 30 June 2021

August 31, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 22 decks. Every deck is listed under its year.